Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Imiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment. To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC. After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15 treatment subjects were clear of BCC. At the 18-month follow-up, no patients had recurrent tumor. Imiquimod 5% cream may be another treatment modality for nodular BCC.